Objectives. The aim of the study was to investigate the functional relevance of the development of structural damage in the spine in patients with early axial spondyloarthritis (axSpA).
Introduction
Function is regarded as one of the most important outcome parameters in chronic rheumatic diseases, including axial spondyloarthritis (axSpA). In up to 40% of patients with axSpA (data obtained mostly from patients with radiographic axSpA, also known as AS), a significant functional impairment with reduced axial mobility is related to structural damage in the spine and may occur in the course of the disease, with a close relationship between the grade of impairment and the duration of the disease [1, 2] . Structural damage in the spine in patients with axSpA includes erosions, sclerosis, squaring of the vertebral bodies, syndesmophyte formation with subsequent ankylosis, joint space narrowing, erosions and ankylosis in the facet joints, spondylodiscitis and fractures [3] . The most typical and, probably, the most functionally relevant radiographic finding of structural damage is a syndesmophyte, which is preferentially evaluated by all commonly used scores for the assessment of structural damage in the spine on spinal radiographs, including the current standard, the modified Stoke AS Spinal Score (mSASSS) [4] .
Available data from cohort studies indicate a clear association between structural damage in the spine (as measured by the mSASSS) and impaired spinal mobility [5, 6] and an association between structural damage and reduction of physical function [6, 7] in advanced axSpA (AS). However, spinal mobility is also strongly dependent on inflammatory activity (as assessed clinically or with MRI) that is potentially reversible [6, 7] . In a recent longterm study with AS patients treated with TNF-a for up to 10 years, functional status remained stable over time despite radiographic spinal progression [8] . Importantly, no studies so far have addressed the question of the functional relevance of the progression of structural damage in patients with early axSpA, although previous data indicated that such a relationship might be rather weak in patients with less baseline structural damage as opposed to patients with ankylosis already present [7] .
The aim of the present work was to determine the functional relevance of the structural damage in the spine in patients with early axSpA.
Methods

Patients
In this study, we included 210 patients with early axSpA [n = 95 with non-radiographic axSpA (nr-axSpA) and symptom duration up to 5 years and n = 115 with AS and symptom duration up to 10 years (Table 1) ] from the GErman SPondyloarthritis Inception Cohort (GESPIC) based on the availability of clinical and radiographic information at baseline and after 2 years of follow-up (Fig. 1) . The design and clinical characteristics of the entire cohort (n = 462) [9, 10] and the detailed description of patient selection have been reported elsewhere [11, 12] . Briefly, patients included in GESPIC were required to have a definite clinical diagnosis of axSpA according to the local rheumatologist. Patients were further classified based on radiographic findings in the sacroiliac joints as AS or as non-radiographic axSpA. Treatment of GESPIC patients was performed according to the local rheumatologist; however, as the cohort was initiated in 2000, the vast majority of the patients were treated without anti-TNF-a agents.
Clinical assessment
Clinical assessment was performed at baseline and every 6 months thereafter until year 2. Clinical disease activity was assessed by the BASDAI [13] using a 010 point numerical rating scale. Functional status was assessed by the BASFI 010 point numerical rating scale [14] , and spinal mobility by the BASMI, a two-step calculation method with the final score between zero and 10 points [15] . The CRP concentration in serum was measured as an objective parameter of inflammatory activity. Other clinical and laboratory disease-relevant parameters were documented as reported previously [9] .
Radiographic assessment
For the assessment of structural damage in the spine at baseline and over time, radiographs of the cervical (lateral view) and of the lumbar spine (lateral and anteroposterior views) were obtained at baseline and after 2 years. Images were centrally collected, digitized, anonymized and scored independently by two trained readers (D.P. and H.H.) according to the mSASSS scoring system [4] , as described in detail elsewhere [12] . Status scores for the mSASSS at baseline and at year 2 were calculated as an average of the scores of both readers. Radiographic spinal progression was defined as an absolute change in the mSASSS over 2 years (mSASSS change score). Structural damage in the sacroiliac joints was assessed in a similar way (as described in detail elsewhere [11] ), according to the system of the modified New York criteria [16] .
Statistical analysis
Methods of descriptive statistics were used for characterizing patients included in the cohort. The main analysis consisted of two parts. Firstly, we performed a linear regression analysis with the BASFI or BASMI change scores (absolute difference between year 2 and baseline values) as the outcome variables, with the mSASSS change score as the main exposure factor. Three models for each outcome were calculated: model 1, an univariable model with the mSASSS change score; model 2, a multivariable model that included mSASSS change score, change in disease activity (BASDAI change score) and baseline BASFI/BASMI values; and model 3, additionally adjusted for the presence of definite radiographic sacroiliitis according to the modified New York criteria (at least grade II bilaterally or at least grade III unilaterally), for CRP as an objective measure of inflammatory activity, for sex and for the HLA-B27 status. The relationship between the BASFI/BASMI change sores and mSASSS change scores was visualized by cumulative probability plots [5] . For this purpose, the mSASSS change scores of all patients were sorted in ascending order and plotted in their precedence with the corresponding cumulative probability of the individual mSASSS change score on the x-axis. The BASFI/BASMI change scores of an individual patient then received the same x-axis value as the mSASSS change score of that patient. This combination of sorted mSASSS and BASFI/BASMI change scores visualizes the association between the parameters.
Secondly, we conducted a longitudinal linear mixed effects model analysis that included status scores of the variables of interest (BASFI/BASMI as outcome variables and mSASSS as the exposure variable). Both baseline and year 2 values of the outcome and exposure variables were included in the analysis that was corrected for the dependencies between the two time-point values of each individual. In a similar manner to the linear regression analysis, three models were built: (i) a univariable model; (ii) a model adjusted for the clinical disease activity (BASDAI); and (iii) a model additionally adjusted for the presence of definite radiographic sacroiliitis, CRP, sex and HLA-B27 status. No assumptions about the covariance structure were made, but an unstructured covariance structure was specified for the intercept and slope effects. As the computational method, the restricted maximum likelihood method was applied.
A sensitivity analysis (mixed model analysis), stratified by the fulfilment of the modified New York criteria (i.e. for the nr-axSpA and AS subgroups), was performed. To exclude the possible bias related to a skewed distribution of the mSASSS, we performed a sensitivity analysis and estimated the values of b based on robust Hampel-type M-estimates that reduce the influence of extreme values. For each parameter estimate (b) obtained in the linear regression or mixed model analysis, a Wald-type 95% CI was calculated. To allow direct comparisons between the impact of structural changes and disease activity on the functional outcomes, the parameters of interest (e.g. mSASSS, BASDAI, BASFI and BASMI scores) were standardized (mean = 0, S.D. = 1), and the corresponding (standardized) parameter estimates (b stand ) were calculated.
Agreement between readers was estimated by the intra-class correlation coefficient (ICC). Statistical analysis was performed using SAS v.9.4 software (SAS Institute Inc., Cary, NC, USA).
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Results
Details of the assessment of spinal radiographs in GESPIC, including inter-reader variability, have been reported elsewhere [12] . Briefly, the agreement between the two readers regarding mSASSS status scores was very good, with an ICC of 0.93 (95% CI: 0.90, 0.94) at baseline and 0.92 (95% CI: 0.90, 0.94) at year 2. The ICC of the mSASSS change score was rather moderate, at 0.43 (95% CI: 0.31, 0.53). The mean, median and the interquartile range for the baseline mSASSS in the entire group were 4.25, 1.0 (0.54.0), with a clearly higher mSASSS in the AS subgroup compared with the nr-axSpA subgroup (Table 2) . Importantly, all but four patients had a baseline mSASSS <24. The mean, median and the interquartile range for the mSASSS change score over 2 years were 0.73, 0.0 (0.01.0) in the entire group, again with a higher change score in AS patients (Table 2) . Likewise, more AS vs nr-axSpA patients demonstrated a worsening of the mSASSS by at least two points (20.0 vs 7.4%, respectively) or by at least four points (9.6 vs 4.2%, respectively) after 2 years. The mSASSS change scores in relationship to the corresponding BASFI/BASMI change scores after 2 years are presented as combined cumulative probability (for the mSASSS) and scatter (for BASFI/BASMI values) plots in Fig. 2 , showing no strong relationship between the parameters analysed.
In the linear regression analysis, the absolute mSASSS change showed an association with the BASFI change after 2 years, with b = 0.09 (95% CI: 0.01, 0.17) in the full adjusted model (model 3; Table 3 ), indicating that radiographic spinal progression of one mSASSS point is associated with a worsening of the BASFI score by 0.09 points. The association between mSASSS and BASMI change scores was somewhat weaker, but the parameter estimation was also less precise, with b = 0.05 (95% CI: À0.04, 0.13) in the full adjusted model (Table 3) . Importantly, the BASDAI change score demonstrated a clear association with the BASFI change score (b = 0.58, 95% CI: 0.47, 0.69) and with the BASMI change score (b = 0.15, 95% CI: 0.04, 0.25; Table 3 ). The standardized b coefficients showed that the BASDAI change score had a higher impact on the change in BASFI/BASMI compared with radiographic spinal progression ( Table 3) .
The longitudinal linear mixed effects model analysis confirmed the results of the linear regression analysis and provided a more precise estimation of the strength of the association between structural damage in the spine (mSASSS) and functional status (BASFI) or spinal mobility (BASMI). Thus, in the full adjusted model (model 3), the mSASSS was associated with BASFI with b = 0.05 (95% CI: 0.03, 0.08) and with BASMI with b = 0.08 (95% CI: 0.05, 0.11) ( Table 4) . These parameter estimates indicate that one mSASSS point would be responsible for 0.05 points higher BASFI and 0.08 points higher BASMI scores irrespective of the disease activity, presence or absence of definite radiographic sacroiliitis and sex in the studied population of early axSpA. This analysis also confirmed a strong association between the functional status/spinal mobility and clinical disease activity as assessed by the BASDAI: the b for BASFI was 0.79 (95% CI: 0.71, 0.86) and for BASMI 0.22 (95% CI: 0.15, 0.30), indicating that an increase in one BASDAI point corresponds to 0.79 higher BASFI and 0.22 higher BASMI values. Calculation of standardized b again showed a larger impact of disease activity (BASDAI) compared with structural damage (mSASSS) on function (BASFI). For the BASMI outcome, however, the relative contribution of structural damage was greater (Table 4 ). In addition, in the direct comparison of the standardized b, the association between the mSASSS and BASMI was, with b stand = 0.41, approximately twice as high as the association between the mSASSS and BASFI (b stand = 0.20; Table 4 ).
In the sensitivity analysis stratified by the fulfilment of the modified New York criteria, mSASSS and BASDAI demonstrated similar effects as in the main analysis. In the AS subgroup, the mSASSS parameter estimates (b) were 0.04 (95% CI: 0.03, 0.06) and 0.08 (95% CI: 0.05, 0.11) for the BASFI and BASMI, respectively, adjusted for BASDAI, CRP, sex and HLA-B27 status. In the nr-axSpA subgroup, the mSASSS showed b = 0.11 (95% CI: 0.00, 0.22) and b = 0.06 (95% CI: À0.04, 0.16) for the association with BASFI and BASMI, respectively, again adjusted for BASDAI, CRP, sex and HLA-B27 status. The sensitivity analysis based on the calculation of the robust Hampeltype M-estimates provided values of b similar to those obtained in the main analysis (Supplementary Tables S1  and S2 , available at Rheumatology online).
Discussion
In the present work, we addressed, for the first time, the question of the functional relevance of structural damage in the spine of patients with early axSpA. Although it is obvious that advanced structural damage, that is, a complete ankylosis of the spine, which is a rather late and nowadays rather rare manifestation of axSpA, is associated with a significant deterioration of spinal mobility [5] , the functional relevance of less extensive damage (e.g. development of one new syndesmophyte over a certain period of time) in patients with axSpA (especially at an early stage) is much less clear.
Landewé et al. [7] demonstrated in the OASIS cohort (patients with advanced AS and mean symptom duration of 20 years) that deterioration of function (measured by BASFI) is particularly evident in the high mSASSS range between 37 and 72, indicating that patients with axSpA at an early stage (with less structural damage in the spine) do not experience a substantial impact of structural damage on function and spinal mobility. It has been shown in the same cohort that clinical disease activity and/or activity of inflammation on MRI is another important and independent determinant of the functional outcome in AS [6, 7] . Most recently, it could be shown that good control of disease activity with a TNF-a inhibitor was able to counterbalance the negative impact of radiographic spinal progression on the functional status in patients with advanced AS over a period of up to 10 years [8] .
In contrast to the above-mentioned cohorts, the GESPIC population consists of patients with early axSpA, with symptom duration of up to 5 years (mean 3.2 years) for the non-radiographic subgroup and of up to 10 years (mean 5.2) for radiographic axSpA. The mean baseline mSASSS was, accordingly, rather low in both subgroups: 2.30 for non-radiographic and 5.86 for radiographic axSpA, with the vast majority of patients (all but four) having mSASSS <24 points. This fact is likely to be responsible for the low functional relevance of radiographic spinal progression in GESPIC patients, with similar results from both linear regression and mixed effects model analysis; however, the mixed model analysis allowed a more precise estimation of the effects. In the full adjusted models from the mixed effect model analysis, b was 0.05 (95% CI: 0.03, 0.08) for the association between mSASSS and BASFI, and 0.08 (95% CI: 0.05, 0.11) for the association between mSASSS and BASMI. These parameter estimates mean that 20 or 12 mSASSS points would be responsible for the difference in one BASFI or one BASMI point, respectively, independently of disease activity (BASDAI, CRP), definite radiographic sacroiliitis and sex. At the same time, clinical disease activity (BASDAI) showed a stronger association with BASFI (based on the comparison of the standardized regression coefficients), indicating that in patients with early axSpA with a low level of structural damage, disease activity seems to be the major factor determining function. For the BASMI, in the analysis of the change scores, the relative contribution of the mSASSS change was again lower compared with the BASDAI change; in the mixed model analysis, however, the opposite effect was observed for spinal mobility, which is most likely to be related to a stronger association between mSASSS and BASMI status scores (used in the mixed model analysis) compared with the change scores.
Both unstandardized and standardized parameter estimates from the mixed model analysis indicate a stronger relationship between mSASSS and BASMI than between mSASSS and BASFI. This might be related to the fact that BASMI is an objective measure of axial mobility, whereas BASFI reflects a patient's perception of the functional limitation, which might change over time, reflecting the process of coping with a chronic disease.
Interestingly, in the OASIS cohort the parameter estimate reflecting association of mSASSS and BASDAI with BASFI were very similar: 0.06 and 0.73, respectively [7] . However, in the OASIS cohort the increase of the BASFI score with increasing mSASSS was mostly observed in patients with an mSASSS status score of >36 points, indicating a possible existence of a threshold for the functional relevance of the structural damage in the spine in axSpA. In GESPIC, 98% of the patients had mSASSS <24 points and, therefore, also clearly below the threshold of functional relevance.
These data have several important practical implications. Firstly, in patients with early axSpA, disease activity seems to be the most important determinant of the functional outcome compared with structural damage in the spine. This allows a clear ranking of the treatment aims: good control of disease activity should be the primary therapy goal, whereas retardation of radiographic spinal progression is less relevant for the functional outcome in the majority of patients owing to a generally low progression rate (median 0.5, mean 0.95 mSASSS points over 2 years in the AS subgroup, and even lower in the non-radiographic subgroup). For example, with a biannual progression rate of one mSASSS point, 40 years would be needed to achieve the mSASSS of 20 (assuming a constant progression rate over time), which is the score that is associated with a BASFI worsening of one point.
Secondly, the relevance of structural damage in the spine, and the ranking of the treatment aims, might be different in a rapidly progressive disease. For example, with an mSASSS progression of four points every 2 years, the clinically relevant value of 20 mSASSS points would be achieved in 5 years. Fortunately, only a minority of axSpA patients demonstrate such a disease course. In GESPIC, a biannual progression rate of four mSASSS points and higher was found in 7.1% of the analysed patients (9.6% in the AS and 4.2 in the nr-axSpA subgroups). For those patients, a treatment strategy with a proven effect on radiographic spinal progression would be highly desirable. Some data indicate that early and longterm anti-TNF-a treatment [17] or treatment with an IL-17 inhibitor [18] might lead to reduction of radiographic spinal progression, but more data from interventional trials are needed to prove those concepts. Certainly, patients with a rapidly progressive course of structural damage in the spine should be identified early if a prevention and/or reduction of progression strategy is to be applied. A combination of clinical parameters (i.e. presence of syndesmophytes, cigarette smoking, high inflammatory activity [12, 19, 20] ) with certain biomarkers (such as MMP3 [21] , sclerostin or dickkopf-1 [22, 23] , VEGF [24] , calprotectin [25] and adipokines [26, 27] ) might help to identify such patients. Our study has some limitations. Firstly, the method of structural damage assessments (mSASSS) that we used includes only the anterior vertebral corners of the cervical and lumbar spine, and does not take into account the thoracic spine and structural damage other than that occurring in the anterior part of the vertebrae. However, no reliable and validated alternative to mSASSS exists nowadays. A scoring system based on CT (including low-dose CT) of the spine might be an alternative to conventional X-rays for the assessment of structural damage in axSpA in the future [28, 29] .
Secondly, BASDAI and BASFI are outcome measures based on patient-reported parameters and therefore might be affected by factors other than those caused by axSpA. Recently, the composite AS disease activity score (ASDAS), including four patient-reported measures and one objective measure (CRP or ESR), was developed [30] . In GESPIC, however, no baseline ASDAS scores could be calculated because one of the parameters required for the calculation of the ASDAS, patient global assessment of disease activity, was only included in the case report form from month 6 onwards. Another parameter reflecting inflammation objectively, namely subchondral bone marrow oedema in the spine on MRI, which was found to be associated with the functional status in AS [6] , could not be analysed because no MRI was performed in the GESPIC within the first 2 years. Thirdly, our data were obtained with a relatively short duration of follow-up (2 years) that makes extrapolation to a long-term period (1020 years) to some extent uncertain.
Finally, there was a substantial drop-out rate within the first 2 years of follow-up that might have been not (completely) at random; however, the analysis of the data from patients who dropped out and who remained in the cohort did not show any meaningful differences in the parameters relevant for the investigated question [12] .
Slow radiographic progression and its limited impact on function is also well known in other rheumatic conditions; for example, in RA. Worsening of function in patients with RA treated with conventional (synthetic) DMARDs (such as  TABLE 3 Association between the change in modified Stoke AS Spine Score and change in BASFI or BASMI after 2 years in the linear regression analysis MTX) alone was also calculated to be rather slow: only 0.13 points of the HAQ score (scale between zero and three) over 5 years, and 0.03 for the combination therapy of a TNF-a inhibitor and MTX, for comparison [31] .
In conclusion, structural damage in the spine and disease activity are both determinants of the functional status and spinal mobility in early axSpA. In patients with early axSpA, who typically have rather slow progression of structural damage in the spine, the disease activity seems to be the major determinant of functional status. In contrast, only in the minority of patients with rapid radiographic spinal progression might structural damage become clinically relevant even early in the course of the disease. Adjusted for the presence of definite radiographic sacroiliitis according to the modified New York criteria for AS (5grade 2 bilaterally or 5grade 3 unilaterally), CRP, sex and HLA-B27 status. mSASSS: modified Stoke AS Spine Score.
